GH 8-K
Guardant Health, Inc. (GH)
8-K
2023-11-06
For: 2023-11-06
View Original
Added on
April 11, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 6, 2023
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2023, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GUARDANT HEALTH, INC. | |||||||||||
| Date: | November 6, 2023 | By: | /s/ Michael Bell | ||||||||
Michael Bell | |||||||||||
Chief Financial Officer | |||||||||||
| (Principal Accounting Officer and Principal Financial Officer) | |||||||||||
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Q3 revenue increased 22% year over year driven by clinical volume growth of 35%
Raises 2023 revenue guidance to $553 to 556 million
PALO ALTO, Calif. November 6, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights
•Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022
•Reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in the third quarter of 2023, representing increases of 35% and 11%, respectively, over the third quarter of 2022
Recent Operating Highlights
•Presented first results of the PEGASUS MRD de-escalation trial at the European Society for Medical Oncology, ESMO, with data suggesting Guardant Reveal may help guide adjuvant treatment of colon cancer
•Received coverage for Guardant Reveal from Geisinger Health Plan
•Surpassed 200 million covered lives for TissueNext
•Launched Guardant360 for clinical use in Japan and biopharma use in China
•Received regulatory approval in Japan for Guardant360 CDx as a companion diagnostic to ENHERTU for treatment of non-small cell lung cancer patients with HER2 mutations
•Published the first paper for Shield demonstrating utility of blood-based CRC screening in Annals of Oncology
“We ended the third quarter with revenue growth of 22%, driven by strong year-over-year growth in clinical volume. We are starting to see the impact of coverage decisions on Guardant360, with uplifts in ASPs and additional tailwinds further strengthening the financial profile of our Therapy Selection business,” said Helmy Eltoukhy, co-founder and co-CEO. “We recently presented exciting MRD data, further demonstrating the clinical utility of our Reveal blood test. We look forward to a strong finish to the year.”
“We are continuing to make steady progress in our screening business with our Shield blood test,” said AmirAli Talasaz, co-founder and co-CEO. “At our recent investor day, we shared some promising new clinical validation data on the next generation of our Shield test. We are also advancing our progress in lung and other indications as we develop Shield into a multi-cancer early detection test.”
Third Quarter 2023 Financial Results
Revenue was $143.0 million for the three months ended September 30, 2023, a 22% increase from $117.4 million for the three months ended September 30, 2022. Precision oncology revenue grew 31%, driven predominantly by an increase in clinical testing volume and biopharma sample volume, which grew 35% and 11%, respectively, over the prior year period. In addition, our clinical testing revenue for the three months ended September 30, 2023 includes a payment of $3.6 million from Medicare related to a successful appeal for claims dated between 2018 and 2020. Development services and other revenue decreased by 37%, primarily due to the timing and amount of milestones related to our partnership agreements and companion diagnostics collaboration projects with biopharmaceutical customers, as well as a reduction in royalty revenue during the three months ended September 30, 2023.
Gross profit, or total revenue less cost of precision oncology testing and cost of development services and other, was $85.4 million for the third quarter of 2023, an increase of $8.5 million from $76.9 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 60%, as compared to 66% for the corresponding prior year period. Precision oncology gross margin was 60% in the third quarter of 2023, as compared to 61% in the prior year period. The reduction is primarily due to changes in product mix. Development services and other gross margin was 59% in the third quarter of 2023, as compared to 93% in the prior year period. The change is primarily due to the inclusion of the cost of processing Shield LDT samples as part of our screening market development activities, for which we are currently booking minimal revenue.
Operating expenses were $199.0 million for the third quarter of 2023, as compared to $221.5 million for the corresponding prior year period. Non-GAAP operating expenses were $177.3 million for the third quarter of 2023, as compared to $200.5 million for the corresponding prior year period.
1
Net loss was $86.1 million for the third quarter of 2023, as compared to $162.0 million for the corresponding prior year period. Net loss per share was $0.73 for the third quarter of 2023, as compared to $1.58 for the corresponding prior year period. The year-over-year reduction in net loss is primarily due to a $31.1 million year-over-year improvement in our loss from operations, a $29.9 million positive change in unrealized gains and losses, and a $9.9 million increase in interest income.
Non-GAAP net loss was $79.2 million for the third quarter of 2023, as compared to $120.8 million for the corresponding prior year period. Non-GAAP net loss per share was $0.67 for the third quarter of 2023, as compared to $1.18 for the corresponding prior year period.
Adjusted EBITDA loss was $79.7 million for the third quarter of 2023, as compared to a $112.8 million loss for the corresponding prior year period.
Free cash flow for the third quarter of 2023 was negative $80.2 million. Cash, cash equivalents and marketable debt securities were $1.2 billion as of September 30, 2023.
2023 Guidance
Guardant Health now expects full year 2023 revenue to be in the range of $553 to $556 million, representing growth of 23% to 24% compared to full year 2022. Guardant Health continues to expect full year 2023 operating expenses to be below full year 2022, driven by efficiency measures and continued leverage of its existing infrastructure, and free cash flow to be approximately negative $350 million in 2023.
Webcast Information
Guardant Health will host a conference call to discuss the third quarter and full year 2023 financial results after market close on Monday, November 6, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.
Non-GAAP Measures
Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of precision oncology testing, non-GAAP cost of development services and other, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, Adjusted EBITDA, and free cash flow.
We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, changes in estimated fair value of noncontrolling interest liability, contingent consideration, acquisition related expenses, amortization of intangible assets, fair value adjustments on marketable equity securities, impairment of non-marketable equity securities and other related assets, and other non-recurring items.
Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax payments; changes in estimated fair value of noncontrolling interest liability; adjustments relating to contingent consideration; and, if applicable in a reporting period, acquisition-related expenses, and other non-recurring items. Free cash flow is defined as net cash used in operating activities in the period less purchase of property and equipment in the period.
We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain other items because we believe that these income (expenses) do not reflect expected future operating expenses. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.
These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.
2
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements relating to Guardant Health’s future results, or regarding the potential benefits and advantages of Guardant Health’s platforms, assays and tests, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Investor Contact:
Media Contact:
Melissa Marasco
+1 650-647-3711
3
Guardant Health, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||
Precision oncology testing | $ | 133,423 | $ | 102,054 | $ | 372,060 | $ | 278,252 | |||||||||||||||
| Development services and other | 9,607 | 15,350 | 36,834 | 44,395 | |||||||||||||||||||
Total revenue | 143,030 | 117,404 | 408,894 | 322,647 | |||||||||||||||||||
Costs and operating expenses: | |||||||||||||||||||||||
| Cost of precision oncology testing | 53,648 | 39,434 | 148,111 | 104,493 | |||||||||||||||||||
| Cost of development services and other | 3,966 | 1,062 | 16,424 | 4,711 | |||||||||||||||||||
| Research and development expense | 93,851 | 100,017 | 277,338 | 267,229 | |||||||||||||||||||
| Sales and marketing expense | 68,934 | 80,370 | 216,100 | 218,405 | |||||||||||||||||||
| General and administrative expense | 36,174 | 41,121 | 118,135 | 126,068 | |||||||||||||||||||
Total costs and operating expenses | 256,573 | 262,004 | 776,108 | 720,906 | |||||||||||||||||||
Loss from operations | (113,543) | (144,600) | (367,214) | (398,259) | |||||||||||||||||||
Interest income | 11,690 | 1,754 | 21,477 | 3,919 | |||||||||||||||||||
Interest expense | (644) | (644) | (1,933) | (1,933) | |||||||||||||||||||
| Other income (expense), net | 16,885 | (18,389) | 56,490 | (18,059) | |||||||||||||||||||
| Fair value adjustments of noncontrolling interest liability | — | — | — | (99,785) | |||||||||||||||||||
| Loss before provision for income taxes | (85,612) | (161,879) | (291,180) | (514,117) | |||||||||||||||||||
| Provision for income taxes | 490 | 115 | 1,226 | 537 | |||||||||||||||||||
| Net loss | $ | (86,102) | $ | (161,994) | $ | (292,406) | $ | (514,654) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.73) | $ | (1.58) | $ | (2.66) | $ | (5.04) | |||||||||||||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 117,736 | 102,289 | 109,791 | 102,065 | |||||||||||||||||||
4
Guardant Health, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share data)
| September 30, 2023 | December 31, 2022 | ||||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 457,339 | $ | 141,647 | |||||||
Short-term marketable debt securities | 697,482 | 869,584 | |||||||||
Accounts receivable, net | 88,801 | 97,256 | |||||||||
Inventory, net | 77,036 | 51,598 | |||||||||
Prepaid expenses and other current assets, net | 26,239 | 31,509 | |||||||||
Total current assets | 1,346,897 | 1,191,594 | |||||||||
Property and equipment, net | 147,671 | 167,920 | |||||||||
Right-of-use assets, net | 161,668 | 174,001 | |||||||||
Intangible assets, net | 9,670 | 11,727 | |||||||||
Goodwill | 3,290 | 3,290 | |||||||||
Other assets, net | 128,035 | 61,453 | |||||||||
Total Assets | $ | 1,797,231 | $ | 1,609,985 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities: | |||||||||||
| Accounts payable and accrued liabilities | $ | 205,266 | $ | 175,817 | |||||||
Deferred revenue | 21,485 | 17,403 | |||||||||
Total current liabilities | 226,751 | 193,220 | |||||||||
| Convertible senior notes, net | 1,139,322 | 1,137,391 | |||||||||
Long-term operating lease liabilities | 192,677 | 210,015 | |||||||||
Other long-term liabilities | 10,182 | 9,179 | |||||||||
Total Liabilities | 1,568,932 | 1,549,805 | |||||||||
Stockholders’ equity: | |||||||||||
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 117,849,155 and 102,619,383 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 1 | 1 | |||||||||
Additional paid-in capital | 2,188,797 | 1,742,114 | |||||||||
Accumulated other comprehensive loss | (5,680) | (19,522) | |||||||||
Accumulated deficit | (1,954,819) | (1,662,413) | |||||||||
Total Stockholders’ Equity | 228,299 | 60,180 | |||||||||
Total Liabilities and Stockholders’ Equity | $ | 1,797,231 | $ | 1,609,985 | |||||||
5
Guardant Health, Inc.
Reconciliation of Selected GAAP Measures to Non-GAAP Measures
(unaudited)
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| GAAP cost of precision oncology testing | $ | 53,648 | $ | 39,434 | $ | 148,111 | $ | 104,493 | |||||||||||||||
| Amortization of intangible assets | (151) | (285) | (448) | (582) | |||||||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | (1,120) | (1,377) | (3,563) | (3,782) | |||||||||||||||||||
| Non-GAAP cost of precision oncology testing | $ | 52,377 | $ | 37,772 | $ | 144,100 | $ | 100,129 | |||||||||||||||
| GAAP cost of development services and other | $ | 3,966 | $ | 1,062 | $ | 16,424 | $ | 4,711 | |||||||||||||||
| Amortization of intangible assets | $ | (201) | $ | — | $ | (603) | $ | — | |||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | $ | (437) | $ | — | $ | (1,391) | $ | — | |||||||||||||||
| Non-GAAP cost of development services and other | $ | 3,328 | $ | 1,062 | $ | 14,430 | $ | 4,711 | |||||||||||||||
| GAAP research and development expense | $ | 93,851 | $ | 100,017 | $ | 277,338 | $ | 267,229 | |||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | (8,611) | (7,256) | (25,877) | (18,857) | |||||||||||||||||||
| Contingent consideration | (531) | (355) | (1,632) | (2,652) | |||||||||||||||||||
| Non-GAAP research and development expense | $ | 84,709 | $ | 92,406 | $ | 249,829 | $ | 245,720 | |||||||||||||||
| GAAP sales and marketing expense | $ | 68,934 | $ | 80,370 | $ | 216,100 | $ | 218,405 | |||||||||||||||
| Amortization of intangible assets | — | (67) | — | (201) | |||||||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | (5,137) | (6,643) | (18,657) | (18,267) | |||||||||||||||||||
| Non-GAAP sales and marketing expense | $ | 63,797 | $ | 73,660 | $ | 197,443 | $ | 199,937 | |||||||||||||||
| GAAP general and administrative expense | $ | 36,174 | $ | 41,121 | $ | 118,135 | $ | 126,068 | |||||||||||||||
| Amortization of intangible assets | (339) | (339) | (1,006) | (1,007) | |||||||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | (6,794) | (5,955) | (18,017) | (31,042) | |||||||||||||||||||
| Contingent consideration | (220) | (390) | (230) | (4,195) | |||||||||||||||||||
| Non-GAAP general and administrative expense | $ | 28,821 | $ | 34,437 | $ | 98,882 | $ | 89,824 | |||||||||||||||
| GAAP loss from operations | $ | (113,543) | $ | (144,600) | $ | (367,214) | $ | (398,259) | |||||||||||||||
| Amortization of intangible assets | 691 | 691 | 2,057 | 1,790 | |||||||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | 22,099 | 21,231 | 67,505 | 71,948 | |||||||||||||||||||
| Contingent consideration | 751 | 745 | 1,862 | 6,847 | |||||||||||||||||||
| Non-GAAP loss from operations | $ | (90,002) | $ | (121,933) | $ | (295,790) | $ | (317,674) | |||||||||||||||
| GAAP net loss | $ | (86,102) | $ | (161,994) | $ | (292,406) | $ | (514,654) | |||||||||||||||
| Amortization of intangible assets | 691 | 691 | 2,057 | 1,790 | |||||||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | 22,099 | 21,231 | 67,505 | 71,948 | |||||||||||||||||||
| Contingent consideration | 751 | 745 | 1,862 | 6,847 | |||||||||||||||||||
| Unrealized gains on marketable equity securities | (16,634) | 13,230 | (84,513) | 13,230 | |||||||||||||||||||
| Impairment of non-marketable equity securities and other related assets | — | 5,261 | 29,054 | 5,261 | |||||||||||||||||||
Fair value adjustments of noncontrolling interest liability | — | — | — | 99,785 | |||||||||||||||||||
| Non-GAAP net loss | $ | (79,195) | $ | (120,836) | $ | (276,441) | $ | (315,793) | |||||||||||||||
6
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| GAAP net loss per share, basic and diluted | $ | (0.73) | $ | (1.58) | $ | (2.66) | $ | (5.04) | |||||||||||||||
| Non-GAAP net loss per share, basic and diluted | $ | (0.67) | $ | (1.18) | $ | (2.52) | $ | (3.09) | |||||||||||||||
| Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted | 117,736 | 102,289 | 109,791 | 102,065 | |||||||||||||||||||
Guardant Health, Inc.
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(unaudited)
(in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| GAAP net loss | $ | (86,102) | $ | (161,994) | $ | (292,406) | $ | (514,654) | |||||||||||||||
| Interest income | (11,690) | (1,754) | (21,477) | (3,919) | |||||||||||||||||||
| Interest expense | 644 | 644 | 1,933 | 1,933 | |||||||||||||||||||
| Other (income) expense, net | (16,885) | 18,389 | (56,490) | 18,059 | |||||||||||||||||||
| Provision for income taxes | 490 | 115 | 1,226 | 537 | |||||||||||||||||||
| Depreciation and amortization | 11,037 | 9,807 | 32,013 | 25,793 | |||||||||||||||||||
| Stock-based compensation expense and related employer payroll tax payments | 22,099 | 21,231 | 67,505 | 71,948 | |||||||||||||||||||
| Contingent consideration | 751 | 745 | 1,862 | 6,847 | |||||||||||||||||||
| Fair value adjustments of noncontrolling interest liability | — | — | — | 99,785 | |||||||||||||||||||
| Adjusted EBITDA | $ | (79,656) | $ | (112,817) | $ | (265,834) | $ | (293,671) | |||||||||||||||
Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities
(unaudited)
(in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net cash used in operating activities | $ | (77,791) | $ | (78,160) | $ | (246,247) | $ | (218,714) | |||||||||||||||
| Purchase of property and equipment | (2,372) | (21,726) | (16,409) | (67,460) | |||||||||||||||||||
| Free cash flow | $ | (80,163) | $ | (99,886) | $ | (262,656) | $ | (286,174) | |||||||||||||||
7